SYNTHESIS OF A NOVEL ARTEMISININ ANALOGUE HAVING POTENT ANTIMALARIALACTIVITY†

Kiyosei Takasu,* Ruriko Katagiri, Yuko Tanaka, Masahiro Toyota, Hye-Sook Kim,# Yusuke Wataya,[#] and Masataka Ihara^{*}

Department of Organic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-8578, Japan # Faculty of Pharmaceutical Sciences, Okayama University, Tsushimanaka 1-1-1, Okayama, Japan E-mail: mihara@mail.pharm.tohoku.ac.jp

Abstract—An artemisinin analogue containing 1,2,4-trioxane structure was designed and synthesized. The compound exhibited significant and selective *in vitro* antimalarial activity.

Malaria is one of the most serious infectious diseases in tropical and subtropical area. Recently, development of a new class of antimalarial drugs is strongly required due to the problem of chloroquineresistant *Plasmodium falciparum*, malaria parasite. Artemisinin (1, qinghaosu),¹ which contains an unusual cyclic peroxy structure, has become an important clinical drug for the treatment of the drugresistant strains. Many of cyclic peroxy compounds as an artemisinin derivative have been synthesized or semi-synthesized, and some of them actually demonstrated effective antimalarial activities.^{2,3} 1,2,4-Trioxane unit was recognized as the essential structure for high efficacy during the investigation of structure-activity relationships about the parent drug. We have designed a modified artemisinin derivative by the introduction of ketocarbonyl oxygen to the C(6) position shown in the partial structure (**2**) as a divergent scaffold for further structural derivation. Several methods for 1,2,4-trioxane framework construction have been reported,⁴ for example, Roth reported the construction of 1,2,4-trioxane structure (3) from dehydrodecaline (4, artemisinic acid) by double oxidation using molecular oxygen.^{4a} Hence, we

† Dedicated to Professor Sho Ito on the occasion of his 77th Birthday.

planned that the analogue (**2**) might be synthesized from the corresponding octalone by utilizing Roth's method. In this communication, we report the synthesis and antimalarial evaluation of a new class of artemisinin analogue. 5

Octalone (**5**) was synthesized as shown in Scheme 1, by an alternative method to that reported by Parker.⁶ Thus, the known bis-allylic alcohol (6)⁶ was acylated with propionyl chloride to give ester (7) in 86% yield. Treatment of **7** with LDA in the presence of TMSCl at low temperature promoted regio- and stereoselective Ireland-Claisen rearrangement.⁷ After its esterification with CH₂N₂, diene (8) having (*l*, *E*) configuration was preferentially obtained in 72% yield (2 steps). The excellent regio- and stereoselectivity could be explained by the formation of *Z*-enolate from **7** which is in agreement with Parker's previous results. THP group of **8** was deprotected in MeOH containing a catalytic amount of *p*toluenesulfonic acid to provide alcohol (**9**) in 94% yield. Oxidation of **9** with PDC, followed by the addition of vinylmagnesium bromide, afforded triene (**10**) in 65% yield for 2 steps. The construction of *cis*-octalone (**5**) was accomplished by Dess–Martin oxidation of **10**, followed by the subsequent spontaneous Diels–Alder reaction of the corresponding intermediate (**11**). Compound (**5**) was obtained in 78% yield as a sole diastereomer, whose configuration was confirmed by the NOESY spectrum. The diastereoselectivity was very high as expected from the previous results.^{7,8}

Scheme 1

Although the oxidation of 5 was investigated under several conditions analogous to Roth's method, $4a$ no 1,2,4-trioxane was obtained. We suspected that the lack of reactivity was due to the relative *trans*configuration between C(6) and C(10) of **5**, whereas Roth's **4** has *cis* stereochemistry. That is, 1,2,4 trioxane would be obtained from *trans*-octalone (**12**).

Treatment of **5** with sodium hydride in THF led to a mixture of ketones (**5**) and (**12**) in a ratio of approximately 55 : 45. Exposure of the epimerized ketone mixture under Roth's conditions gave *endo*- peroxy compound (**14**) in 5% yield based on **5**. Namely, **12** was irradiated with 100W tungsten lump in acetone containing catalytic amount of methylene blue under $O₂$ current to produce tertiary hydroperoxide (**13**) *in situ*. Treatment of crude **13** with a catalytic amount of trifluoroacetic acid and atmospheric oxygen afforded 14.⁹ The ¹H NMR spectrum exhibited characteristic singlet (5.80 ppm), which corresponds to acetal hydrogen attached to $C(1)$. The IR spectrum indicated the existence of hydroxyl function $(3500-3200 \text{ cm}^{-1})$ and peroxy ether (1160 cm^{-1}) . The structure of 14 was firmly determined by the 2D NMR technique. Due to the intramolecular hydrogen bonding, β-hydroxyl group would be thermodynamically favorable. Consequently, the lactonization could not occur although artemisinin analogues generally undergo lactonization.

Scheme 2

(a) NaH, rt; (b) O_2 , methylene blue, hv , 0 °C; (c) CF_3CO_2H , O_2 , rt

Antimalarial effectiveness of 1,2,4-trioxane (**14**) and synthetic intermediate (**12**) against *P. falciparum* was investigated *in vitro* (Table 1).10 Compound (**14**) possesses a remarkable antimalarial activity, $IC_{50} = 3.9$ x 10^{-8} (M), comparable to natural artemisinin (**1**). Notably, the selective toxicity is quite high (>1,000). On the contrary, **12** having no trioxane structure showed much weaker activity than **14**.

Table 1 *In Vitro* Antimalarial Activities and Cytotoxicities

	IC_{50} (M)		selective
compound	P. falciparum ^a FM3A cell ^b		toxicity c
(\pm) -14	3.9×10^{-8}	2.4×10^{-5} d > 1,000	
(\pm) -12	5.8 x 10^{-5} e		
(+)-artemisinin (1) 7.9×10^{-9}		1.0×10^{-5}	1,300

 a Chloroquine sensitive strain (FCR-3). b Mouse mammary tumor FM3A cells representing a model of host. ^c Selective toxicity = IC₅₀ value for FM3A / IC₅₀ for *P.falciparum.* d IC₂₂ value (78% Growth of FM3A cells was observed.) e^{i} IC₂₂ value (78% Growth of P. falciparum was observed.)

In summary, a new class of artemisinin analogue having a keto carbonyl group at the C(6) position was synthesized and evaluated for the antimalarial activity. Its promising activity suggests a possibility of a lead compound for antimalarial agent. Further modification of analogue and the optimization of its synthetic strategy are now in progress.

ACKNOWLEDGEMENT

This work was partially supported by a Grant-in-Aid for Scientific Research on Priority Areas (No. 1147202) from the Ministry of Education, Science, Sports, and Culture, Japan.

REFERENCES AND NOTES

1. (a) D. L. Klayman, *Science*, 1985, **228**, 1049. (b) W.-S. Zhou and X.-X. Xu, *Acc. Chem. Res.*, 1994,

27, 211.

- 2. For reviews. See, (a) S. R. Meshnick, T. E. Taylor, and S. Kamchonwongpaisan, *Microbiol. Rev.*, 1996, **60**, 301. (b) A. K. Bhattacharya and R. P. Sharma, *Heterocycles*, 1999, **51**, 1681.
- 3. H.-S. Kim, Y. Shibata, Y. Wataya, K. Tsuchiya, A. Masuyama, and M. Nojima, *J. Med. Chem*., 1999, **42**, 2604.
- 4. (a) R. J. Roth and N. Acton, *J. Chem. Ed.*, 1991, **68**, 612. (b) C. H. Oh, H. J. Kim, S. H. Wu, and H. S. Won, *Tetrahedron Lett.*, 1999, **40**, 8391 and references cited therein.
- 5. This work is under patent pending. M. Ihara, K. Takasu, H.-S. Kim, and Y. Wataya, C07D496/12.
- 6. K. A. Parker and J. G. Farmar, *J. Org. Chem*., 1986, **51**, 4023.
- 7. R. E. Ireland, R. H. Mueller, and A. K. Willard, *J. Am. Chem. Soc.*, 1976, **98**, 2868.
- 8. (a) K. Mori and M. Waku, *Tetrahedron*, 1984, **40**, 305. (b) D. F. Taber and B. P. Gunn, *J. Am. Chem. Soc.*, 1979, **101**, 3992.
- 9. Spectral data for **14**: ¹H NMR (500 MHz, CDCl₃) δ 1.20 (3H, d, *J* = 7.0 Hz), 1.22–1.84 (4H, m), 1.86–1.89 (1H, m), 1.91 (3H, s), 2.05–2.20 (2H, m), 2.27–2.38 (2H, m), 2.54–2.61 (2H, m), 2.78 (1H, m), 3.68–3.71 (1H, m), 3.69 (3H, s), 5.80 (1H, s); IR (neat) ν 3500–3200, 1730, 1710, 1160 cm⁻¹.
- 10. H.-S. Kim, H. Miyake, M. Arai, and Y. Wataya, *Parasitol. Int.*, 1998, **47**, 59.